Guotou Securities: The market share of listed pharmacies continues to increase, and the growth potential is expected to lead the industry.
In the context of a slowdown in the industry's growth rate, listed pharmacies are expected to achieve growth rates higher than the industry by virtue of their continuous rapid expansion of stores.
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
Shanghai supports the use of AI technology in drug research and development, and continues to increase its support for the development of innovative drugs.
On July 30, the Shanghai Municipal People's Government Office issued several opinions on supporting the innovative development of the entire biomedical industry chain.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
NEW RAY MEDIC: SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORTFOR THE YEAR ENDED 31 DECEMBER 2023
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
New Ray Medicine Shareholders to Vote July 16 on Purchase Contract
Xinrui Pharmaceutical (06108.HK) signed a cornerstone investment agreement with Jiangxi Yimai Sunshine Group
Gelonghui, May 30, 丨 Xinrui Pharmaceutical (06108.HK) announced that on May 28, 2024, China Xinrui (a wholly-owned subsidiary of the company, as an investor) signed a cornerstone investment agreement with Jiangxi Yimai Sunshine Group, CITIC Securities (Hong Kong) Limited (as the sole sponsor) and CITIC Lyon Securities Limited (as the sole sponsor and overall coordinator). Based on this, China Xinrui has agreed to subscribe for investors' shares at the sale price. The total investment in investors' shares is HK$12 million (excluding brokerage commissions and levies that China Emerging Companies will pay on investors' shares).
Yimaiyangguang (02522.HK) is expected to be listed on June 7th, introducing cornerstone investors such as United Imaging Medical.
On May 30th, Gleamray Sunshine (02522.HK) announced that the company plans to issue 17.816 million shares globally, 1.782 million shares in Hong Kong, and 16.034 million shares internationally. The IPO will be open for subscription from May 30th, 2024 to June 4th, 2024, with the expected pricing date being June 5th. The offering price will be HKD 14.60-16.80 per share, with a trading unit of 500 shares. Citic Securities will be the sole sponsor and it is expected that the shares will commence trading on the Main Board of the Stock Exchange of Hong Kong on June 7th, 2024. The company is a leading medical imaging specialized medical group in China.
Xinrui Pharmaceutical (06108) subsidiary plans to increase capital injection into Shengzhou Xinrui Wanlin enterprise management
Xinrui Pharmaceutical (06108) issued an announcement. On May 24, 2024, Zhejiang, an indirect wholly-owned subsidiary of the company...
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
New Ray Medicine International Unit to Buy 16% Stake in Pharmaceutical Firm
A subsidiary of Xinrui Pharmaceutical plans to acquire 16% of the issued share capital of China Nu Wa Pharmaceutical Group
Xinrui Pharmaceuticals (06108) announced that on May 16, 2024 (after the trading period), the buyer Major Bright Holdings Limited (an indirect wholly-owned subsidiary of the company) entered into a sales agreement with the seller Yu Wenyong (as an independent third party). According to this, the seller conditionally agreed to sell and the buyer conditionally agreed to purchase shares for sale at a cost of HK$17.28 million. Shares for sale account for 16% of the issued share capital of the target company China Nu Wa Pharmaceutical Group Co., Ltd. The target group is mainly engaged in the manufacture, sale and distribution of pharmaceutical products in China. The announcement stated,
Xinrui Pharmaceutical (06108) subsidiary plans to acquire 16% of China's issued share capital of China Nu Wa Pharmaceutical Group for HK$17.28 million
Xinrui Pharmaceuticals (06108) issued an announcement. On May 16, 2024 (after the trading session), the buyer Majo...
NEW RAY MEDIC: 2023 Annual Report
Xinrui Pharmaceuticals (06108) announced annual results. The net loss attributable to shareholders was about HK$22.2 million, a year-on-year narrowing of about 71.5%
According to the Zhitong Finance App, Xinrui Pharmaceutical (06108) announced results for the year ended December 31, 2023, with revenue of about HK$50.2 million, a year-on-year decrease of 44.1%; net loss attributable to the company's owners was about HK$22.2 million, a year-on-year decrease of about 71.5%; and a loss of 1.33 HK cents per share. The decline in revenue was mainly due to the further strengthening of the hierarchical classification management policies for the adoption of antimicrobials in many regions of mainland China, and the adverse effects continued. As a result, demand for the Group's main product, second-generation cephalosporin products (1.0g), declined this year.
NEW RAY MEDIC: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
New Ray Medicine International Forecasts Decline in 2023 Loss
No Data